OLIG2 and glioblastoma: In our recent study evaluating the efficacy of osimertinib against EGFRvIII+ glioblastoma, we found that compared to D317, D10-0171 exhibited increased expression of growth-promoting GSC markers such as OLIG2, and resistance to growth inhibition by EGFR-TKIs [12].